There was no statistical difference between the multimodality treatment group and the chemotherapy only group in age, sex, histologic differentiation, HER2 status, tumor location, tumor marker level at diagnosis, number of metastatic sites, previous curative resection, and follow-up period. This evidence concerns the gene ERBB2 and neoplasm.